Please login to the form below

Not currently logged in
Email:
Password:

Tepmetko

This page shows the latest Tepmetko news and features for those working in and with pharma, biotech and healthcare.

AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China

AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China

In March  2020, Merck KGaA’s oral MET inhibitor Tepmetko (tepotinib) became the first from this drug class to receive approval in MET-positive NSCLC, after gaining a green light from ... Since then, Tepmetko has received approval in the same patient

Latest news

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....